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Abstract
OBJECTIVES: We reviewed our combined clinical outcome in patients who underwent lung transplantation after ex vivo lung perfusion
(EVLP) and compared it to the contemporary control group.
METHODS: At 2 Scandinavian centres, lungs from brain-dead donors, not accepted for donation but with potential for improvement,
were subjected to EVLP (n = 61) and were transplanted if predefined criteria were met. Transplantation outcome was compared with that
of the contemporary control group consisting of patients (n = 271) who were transplanted with conventional donor lungs.
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RESULTS: Fifty-four recipients from the regular waiting list underwent transplantation with lungs subjected to EVLP (1 bilateral lobar, 7 sin-
gle and 46 double). In the EVLP and control groups, arterial oxygen tension/inspired oxygen fraction ratio at arrival in the intensive care
unit (ICU) was 30 ± 14 kPa compared to 36 ± 14 (P = 0.005); median time to extubation was 18 h (range 2–912) compared to 7 (range
0–2280) (P = 0.002); median ICU length of stay was 4 days (range 2–65) compared to 3 days (range 1–156) (P = 0.002); Percentage of
expected forced expiratory volume at 1s (FEV1.0%) at 1 year was 75 ± 29 compared to 81 ± 26 (P = 0.18); and the 1-year survival rate was
87% [confidence interval (CI) 82–92%] compared to 83% (CI 81–85), respectively. Follow-up to a maximum of 5 years did not show any sig-
nificant difference in survival between groups (log rank, P = 0.63).
CONCLUSIONS: Patients transplanted with lungs after EVLP showed outcomes comparable to patients who received conventional organs
at medium-term follow-up. Although early outcome immediately after transplantation showed worse lung function in the EVLP group, no
differences were observed at a later stage, and we consider EVLP to be a safe method for increasing the number of transplantable organs.
Keywords: Ex vivo lung perfusion • Lung transplantation • Lung reconditioning
INTRODUCTION
Lung transplantation (LTx) is an established treatment option for
patients with end-stage pulmonary disease. The number of lung
transplant procedures performed annually has consistently been
increasing with encouraging and improving long-term results [1, 2].
The published rate of accepted organs from multiorgan donors
varies from 15% to 50% [3], implying that in some regions or
centres, up to 85% of available lungs are declined. Extended
donor criteria and a more aggressive approach to optimize po-
tential donor lungs in situ may increase organ availability in
centres with a low acceptance rate.
Ex vivo lung perfusion (EVLP) has proven its potential by suc-
cessfully differentiating between reversible and non-reversible
lung pathology prior to transplantation [4–12]. Uncertainty over
donor lung quality is often the reason for rejecting the organs.
Some of these organs may not meet strict transplantation criteria
at first evaluation, but in reality they may have the function that
allows transplantation. In our setting, the evaluation of marginal
organs ex vivo by the transplant team has increased the yield of
organs available for transplantation. In the future, EVLP may also
be a means of organ improvement by using different treatment
strategies during EVLP.
The first successful LTx after EVLP was reported by Steen et al.
[13] in 2001. EVLP has since gained increasing interest in trans-
plant centres around the world. In 2008, Cypel et al. [14] in
Toronto published an article on the extended EVLP assessment of
lung function using a novel strategy, which was the starting point
for the ‘Toronto protocol’. In 2011, the group published their first
clinical study [15]. This was followed by short- to mid-term results
in smaller series and case reports [4, 16–20], while publications
on long-term results are still scarce [6, 21].
In our 2 Scandinavian centres, EVLP programmes were intro-
duced in clinical practice in 2011 and 2012 [10, 22, 23]. Herein, we
review the outcomes for patients who were transplanted with EVLP
lungs and compare results to a control group of recipients who
were transplanted with conventional lungs during the same period.
MATERIALS AND METHODS
Study design
The ethics committees of the University of Gothenburg and the
University of Copenhagen approved this study. All patients were
informed and consented to the possibility of receiving organs
that had undergone EVLP when they were listed for
transplantation. The organs were otherwise matched according
to standard criteria.
At the outset, inclusion criteria for EVLP evaluation of rejected
donor lungs were an arterial oxygen tension/inspired oxygen
fraction (PaO2/FiO2) ratio <40 kPa and/or X-ray findings that
were consistent with pulmonary oedema. Later, criteria were
expanded to also include donor lungs for which it was not pos-
sible to properly evaluate in the donor (patient on veno-arterial
extra corporeal membrane oxygenation (va-ECMO)), or ones
with suspected lung injury (donors with pulmonary embolism or
severe trauma as cause of death), or donor history, radiological
or macroscopic findings suggesting severely impaired lung func-
tion that prevents the use of the organs. The decision to proceed
to EVLP with lungs that were rejected for direct use was made
after discussion between at least 2 transplant surgeons.
The procurement of the donor lungs was performed according
to the local standard protocol. During transport, the organs were
stored cold on ice. EVLP was performed at the recipient hospital.
Patients from our 2 centres were prospectively and consecutively
included in this study between January 2011 and December 2015,
and they were followed up until the end of December 2016. Lungs
from brain-dead donors that were primarily rejected for transplant-
ation were considered for EVLP. Lungs that achieved acceptable
lung function during EVLP were transplanted. In both centres, ac-
ceptable lung function was defined as follows: (i) PaO2/FiO2 ratio
>40 kPa; (ii) pulmonary vascular resistance (PVR) and pulmonary
compliance deemed normal under EVLP conditions (350–650 dyns/
cm5 and >50 ml/cm H2O, respectively) and not deteriorating during
EVLP; and (iii) macroscopic appearance and manual inspection with-
out major pathology. Outcomes in recipients who were transplanted
with lungs after EVLP or without prior EVLP were compared.
Ex vivo lung perfusion
EVLP at our 2 centres was performed based on a modified ver-
sion of the procedure described by Steen et al. [24]. Equivalent
protocols were applied at both institutions using the Vivoline LS1
device, in which lungs were perfused with Steen solution mixed
with red blood cells to a haematocrit of 10–15%, 10 000 U of
heparin and 100 mg of meropenem. Evaluation was performed at
full perfusate flow. Acceptance criteria differed between our 2
centres with regard to Pao2/FiO2 (see below).
Gothenburg. The EVLP procedure has been described in de-
tail previously [25]. Perfusion of the lungs was restricted to 70 ml/
min/kg donor weight. The pressure limit of the pulmonary artery
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(PA) was increased to 20 mmHg during the evaluation phase. PA
flow and thereby pressure was gradually increased. Mechanical
ventilation with a positive end-expiratory pressure of 5 cm H2O
and a tidal volume of 6–8 ml/kg were initiated at 32C. At this
stage, a bronchoscopy was performed to clear any secretions
and to inspect the bronchial tree. At 36C, a lung recruitment
manoeuvre with increasing positive end-expiratory pressure lev-
els under visual inspection was performed. Repeated samples for
gas analysis were drawn from the left atrium and compared to
simultaneous samples from the PA. The pO2 of the deoxygenated
blood in the PA never exceeded 7 kPa. A physiological dead
space fraction (calculated as PaCO2–EtCO2/PaCO2), static lung
compliance and PVR were continuously monitored.
The acceptance of organs for transplantation was based on the
following criteria: (i) a PaO2/FiO2 ratio >40 kPa during the evalu-
ation phase; (ii) stable haemodynamic and respiratory variables
(PVR, peak airway pressures and lung compliance) during EVLP.
No absolute cut-off levels for these variables were used. A negative
trend with deterioration of physiological variables during EVLP was
considered a relative contraindication for transplantation; (iii) the
absence of macroscopic signs of pneumonic infiltrates or lung
infarctions; and (iv) a normal collapse test. Accepted lungs were
surface cooled in the EVLP system awaiting transplantation.
Copenhagen. The EVLP procedure has been described in de-
tail previously [23]. Lung protective ventilation was initiated at
32C. At 36C, blood gases were drawn to assess whether the
evaluation phase could be entered. Evaluation was performed at
36C, following lung recruitment manoeuvres and bronchoscopy.
Lungs were approved if pCO2 < 6 kPa and if pO2 > 50 kPa at FiO2
= 1.0 or pO2 > 13 kPa at FiO2 = 0.21. The collapse test was per-
formed to evaluate pulmonary oedema. Accepted lungs were
surface cooled in the EVLP system awaiting transplantation.
Lung transplantation and outcome analyses
Recipient characteristics are reported in Table 1. Surgery was per-
formed as to local preference and routine, either via bilateral se-
quential thoracotomy or sternotomy, either with or without
extracorporeal circulation. After the operation, all patients
received care and treatment according to standard protocols. The
ventilator time was defined as time to extubation in hours.
The time in intensive care unit (ICU) was defined as the number
of days from ICU arrival to general ward discharge. If the recipient
was re-intubated during the index procedure hospitalization, the
ventilator time was defined as the total ventilator treatment time.
Statistical analyses
Continuous data are presented as mean and standard deviation
or median and range. Categorical data are presented as fre-
quency and/or percentage. Differences between groups were
evaluated with the Mann–Whitney U-test or the Student’s t-test.
A P-value of <0.05 was considered as statistically significant.
Kaplan–Meier curves were used for survival plots and the log-
rank test for comparison of proportional survival between the
groups. The Shapiro–Wilk test was used for testing normality.
Cox proportional hazard regression was used to examine the
relative risk of death between the studied groups. A test of the
proportional hazards, which was a required assumption of Cox
regression, was performed using a formal significance test based
on the unscaled and scaled Schoenfeld residuals.
RESULTS
During the 4-year study period, from January 2011 to December
2015, with Gothenburg initiating its clinical EVLP programme in
January 2011 and Copenhagen in May 2012, lungs from 1013
donors were offered to our 2 centres (Fig. 1). This number
includes all brain-dead donors (donation after circulatory death
(DCD) donation was not performed in our 2 countries during the
study period), irrespective of donor age. Patients who underwent
Table 1: Recipient characteristics
Recipient variables EVLP
(n = 54)
Conventional
(n = 271)
Age (years), mean ± SD 52 ± 12 51 ± 13
Diagnosis (%)
IPF 24 25
PAH 2 6
COPD 33 28
Alfa-1-antitrypsin deficiency 6 13
CF 20 12
Other 15 16
Patients on preoperative mecha-
nical ventilation, n (%)
5 (9.3) 12 (4.4)
ECMO, n (%) 1 (1.9) 16 (5.9)
CF: cystic fibrosis; COPD: chronic obstructive pulmonary disease; ECMO:
extracorporeal membrane oxygenation; EVLP: ex vivo lung perfusion; IPF:
interstitial pulmonary fibrosis; PAH: pulmonary artery hypertension; SD:
standard deviation.
Figure 1: All donor lungs offered to our 2 centres during the study period.
Bilateral: bilateral sequential lung transplantation; EVLP: ex vivo lung perfusion;
Single: single lung transplantation; Tx: transplantation.
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all other contemporary LTx (n = 271) procedures during the same
time interval, with organs accepted according to standard selec-
tion criteria not requiring EVLP, were included as the control
group. Retransplantations during the study period were excluded.
Ex vivo lung perfusion
In our combined cohort, 61 patients with donor lungs underwent
EVLP. The mean donor PaO2/FiO2 ratio was 30.6±12 kPa (exclud-
ing 2 donors on VA-ECMO). In cases where donor PaO2/FiO2
met standard acceptance criteria, reasons for EVLP were as fol-
lows: atelectasis unresponsive to ventilator lung recruitment
manoeuvres (n = 4), infiltrates on pulmonary X-ray (n = 4), and
donor on VA-ECMO (n = 2). No EVLP was performed for logistical
reasons.
After EVLP, 47 pairs of lungs were deemed transplantable. In
one of these cases, the lung pair was split and transplanted in 2
different recipients. In 1 case, bilateral bilobar transplantation
was performed. In 5 cases, one of the lungs was used for single
LTx, and the other discarded after EVLP. The conversion rate
expressed as the total number of lungs transplanted to the total
number of lungs placed on EVLP (99/122) was 81%. Another way
of expressing conversion rate would be that in 85% of EVLP runs
either one or both lungs were transplanted. EVLP data during
evaluation are presented in Table 2.
Transplantation
Forty-six bilateral, 1 bilobar and 7 single LTxs were performed
after EVLP, compared to 246 bilateral and 37 single LTxs in the
control group (Table 3). The use of intraoperative extracorporeal
circulation or extracorporeal membrane oxygenation was similar
in the 2 groups.
Early postoperative results
One patient in the EVLP group and 4 in the conventional group
died within the first 48 h after transplantation (Table 3). Death in
none of these cases was attributable to insufficient lung function.
PaO2/FiO2 at arrival in ICU was 30 ± 14 kPa in the EVLP group
compared to 36 ± 14 in the control group (P = 0.005). When com-
paring the EVLP group to the control group, median time to
extubation was 18 h (range 2–912) vs 7 h (range 0–2280 h)
(P = 0.002), median ICU stay was 4 days (range 2–65) vs 3 days
(range 1–156) (P = 0.002) and time to discharge to home or a re-
habilitation facility was 30 days (range 17–112) vs 28 days (range
12–268), respectively (P = 0.35).
Follow-up
One-year retransplantation-free survival was 87% [confidence
interval (CI) 82–92%] in the EVLP group and 83% (CI 81–85%) in
the conventional group. Cumulative retransplantation-free sur-
vival did not differ significantly between the groups (log rank,
P = 0.63) (Fig. 2) during the entire period in our combined
cohorts. Causes of death in the EVLP group are reported in
Table 4.
Cox proportional hazards regression was performed. The haz-
ard ratio for EVLP was 1.14 (95% CI 0.67–1.93), P = 0.62. The as-
sumption of proportional hazards was tested as described in the
statistics section and fulfilled. Cox regression did not show a sig-
nificant difference in survival between groups. Data indicated a
14% higher relative risk for death or retransplantation in the
EVLP group with a wide CI that did not reach significance.
Pulmonary function test
FEV1.0% was 75 ± 29% and 81 ± 26% at 1 year in the EVLP and
control groups, respectively (P = 0.18).
DISCUSSION
The main finding of the present study in 2 Scandinavian centres
was that the cumulative retransplantation-free survival for up to
Table 2: EVLP data from lung pairs later transplanted (n = 53)
EVLP variables Mean Median Range
PaO2 (kPa)
a 58.5 ± 10.0 57.8 31.4–79.2
Compliance (ml/cm H2O)
a 55 ± 28 52 19–151
EVLP reconditioning time (min) 200 ± 94 175 76–577
EVLP weight change (g) +49 ± 236 54 -600 ± 500
aFinal measurement at EVLP evaluation forming the basis for the decision
to accept the organs.
EVLP: ex vivo lung perfusion.
Table 3: Intra- and postoperative characteristics
Variables EVLP Control P-value
Number of patients 54 271
Single lung transplantation, n (%) 7 (13) 37 (14)
Bilateral sequential lung transplantation (including one bilobar LTx), n (%) 47 (87) 234 (86)
Intraoperative ECC/ECMO, n (%) 29 (54) 125 (46)
PaO2/FiO2 at arrival in ICU (kPa), mean ± SD 30 ± 14 36 ± 14 0.005
Time to extubation (h), median (range) 18 (2–912) 7 (0–2280) 0.002
ICU stay (days), median (range) 4 (2–65) 3 (1–156) 0.002
Time to discharge (days), median (range) 30 (17–112) 28 (12–268) 0.35
FEV1% at 12 months, mean ± SD 75 ± 29 81 ± 26 0.18
1-Year survival 87% (CI 82–92%) 83% (CI 81–85%)
CI: confidence interval; ECC: extracorporeal circulation; ECMO: extracorporeal membrane oxygenation; EVLP: ex vivo lung perfusion; FEV1: forced expiratory venti-
lation in the 1 s; ICU: intensive care unit; LTx: lung transplantation; PaO2/FiO2: arterial oxygen tension/inspired oxygen fraction; SD: standard deviation.
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5 years in patients transplanted with EVLP-evaluated lungs was
comparable to a control group of all contemporary patients
transplanted with non-EVLP organs. PaO2/FiO2 at arrival in ICU
was lower, and time to extubation and time in ICU were signifi-
cantly longer in the EVLP group. There was no difference in time
to discharge from hospital, lung function at 1 year, or mortality
or need for retransplantation. This indicates that the selection of
donor organs for EVLP, as well as the selection of lungs for
transplantation after EVLP, was adequate. This study is based ex-
clusively on organs transplanted from brain-dead donors.
During the study period, the acceptance rate at our 2 institu-
tions for conventional lungs without prior EVLP was 27%, a num-
ber higher than what many international centres report [1, 2]. Of
the organs not fulfilling standard criteria, 61 were selected for
EVLP evaluation. In contrast to others, while applying wider indi-
cations for EVLP [6] we have only accepted lungs with poor gas
exchange or other clear contraindications for transplantation for
EVLP. Fifty-four patients were transplanted with EVLP lungs, in
which the conversion rate for EVLP-evaluated lungs was 81–85%.
The selection for EVLP is still mainly based on clinical judgement,
but the criteria for the selection of donor lungs suitable for EVLP
will need to be explored further in future studies.
Implementing an EVLP programme can significantly increase
the number of organs available for transplantation, possibly even
utilizing up to as many as 50% of donor lungs. Centres with an al-
ready high acceptance rate can expect to have a significant add-
ition of available organs by the introduction of EVLP.
EVLP strategies at our 2 institutions have been described previ-
ously [22, 23] and are based on the protocol initially developed
by Steen et al. [13], using a cellular perfusate with banked blood
added to a haematocrit of 10–15%, an open left atrium and
evaluation of the lungs at relatively high pressure and flow. Since
the introduction of EVLP, this protocol has been implemented at
our institutions after minor modifications. No study has so far
presented a validated algorithm for which lungs to accept for
transplantation following EVLP. P/F-ratio and macroscopic ap-
pearance are still the main determinants of whether to proceed
to transplantation, while other variables such as compliance, PVR
dynamics and dead space fraction may provide supporting
evidence.
The optimal yield of transplantable organs after EVLP depends
on several factors, including selection criteria for considering
EVLP, the experience of the transplant team and thresholds for
proceeding to transplantation. At our two centres, the decision
to use initially non-acceptable marginal donor lungs was initially
made by junior retrieval surgeons in the donor hospital, followed
by more experienced surgeons and anaesthesiologists after EVLP.
Figure 2: Survival and freedom from retransplantation after lung transplant-
ation. The combined EVLP and control groups had a similar survival and free-
dom from retransplantation after transplantation. EVLP: ex vivo lung perfusion.
Table 4: Cause of death in EVLP recipients
Diagnosis Type of transplantation Time after operation Causes
PAH Bilateral sequential 31 months Chronic graft failure
Fibrosis Bilateral sequential 24 months Squamous cell carcionoma, bronchial stenosis after radiotherapy
Fibrosis Bilateral sequential 18 months Graft failure secondary to pneumonia
a1AT deficiency Bilateral sequential 25 months Graft failure secondary to recurrent pulmonary infections
COPD Bilateral sequential 18 months Graft failure secondary to pneumonia
CF Bilateral sequential 5 months Graft failure secondary to pneumonia
CF Bilateral sequential 13 months Chronic graft failure, bronchial stenosis
COPD Bilateral sequential 36 months Respiratory failure secondary to recurrent infections and rejection
COPD Bilateral sequential 5 months PRES, CNI intolerance, rejection
Fibrosis Bilateral sequential 1 day Bleeding, graft failure, ECMO
Fibrosis Bilateral sequential 1 day Bleeding
Fibrosis Bilateral sequential 61 months Unexpected death during sleep at home
Fibrosis Bilateral sequential 9 months BOS
Fibrosis Bilateral lobar 14 months Pulmonary embolism and BOS
Fibrosis Single 18 months BOS
a1AT: alpha 1-antitrypsin; BOS: bronchiolitis obliterans; CF: cystic fibrosis; CNI: calcineurin inhibitor; COPD: chronic obstructive pulmonary disease; ECMO: extra-
corporeal membrane oxygenation; PRES: posterior reversible encephalopathy syndrome; PAH: pulmonary artery hypertension.
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It could be argued that sending more experienced senior sur-
geons for organ retrievals could further increase the acceptance
rate, thereby avoiding the quite substantial costs associated with
EVLP evaluations in selected cases.
During the introduction of the EVLP programme at our 2
centres, funding was provided by research grants. However, after
being adopted as a clinical routine procedure, it is now financed
via the tax-based, general public health care system, in line with
other medical procedures.
In this study, the conversion rate was 81%, which is high, but
in agreement with most previous studies reporting a conversion
rate between 46% and 100% [4, 6, 22]. The DEVELOP-UK study
stands out in this aspect, reporting a conversion rate of only 34%
[26]. It was an ambitious, multicentre observational study that
compared EVLP to conventional lungs, which was terminated
early due to slow recruitment and concerns about high levels of
the use of ECMO in the EVLP arm. One could speculate that one
reason for the low conversion rate may be that several of the
participating centres had little experience in EVLP and conse-
quently adopted a more conservative approach in accepting
organs.
It could be argued that donor lungs that other centres would
have considered for conventional transplantation were exposed
to unnecessary EVLP in our centre, i.e. selecting very good lungs
for EVLP. However, as our acceptance rate is already compara-
tively high, in combination with the fact that lungs subjected to
EVLP in this study were first declined by multiple centres for con-
ventional transplantation, we do not believe that other centres
would have used any of these lungs for conventional transplant-
ation. The high conversion rate may indicate that even more
lungs should undergo EVLP, hopefully resulting in more lungs for
transplantation. Martens et al. [27] published a retrospective
database analysis of unused lung donors, identifying a large po-
tential for EVLP to further increase the donor pool in transplant
centres, even when the majority were already extended criteria
donor lungs.
Different strategies for EVLP have been suggested and reported
[14]. This study indicates that good long-term results can be
achieved with more than 1 EVLP protocol. In a recently published
study, where 2 EVLP strategies were compared in a porcine ex-
perimental setup, we could not show any significant difference in
lung performance [28].
Our results indicate a significantly longer time on ventilator and
a longer length of stay in ICU in patients receiving EVLP-treated
lungs. This is not a surprise, because functionally less optimal organs
were selected for EVLP and later transplanted. The time on EVLP is
relatively short with a median of 175 min (range 76–577 min). It has
been suggested that longer EVLP time could reduce oedema. Our
clinical data show that lungs might lose or gain weight, i.e. fluid,
during EVLP, and EVLP does not necessarily decrease oedema con-
tent in a specific pair of lungs. This has further been evaluated by
our group in a recent publication [29]. Hemofiltration during EVLP,
to increase perfusate oncotic pressure and thereby optimize oe-
dema reduction, may be a way forward [25].
Our data show a comparable outcome in patients who were
transplanted with EVLP lungs and controls. One-year retransplan-
tation-free survival was close to 90%. There is no statistically sig-
nificant difference between groups in our study with regard to
long-term survival or freedom from retransplantation; however,
numbers at risk are very low beyond 3 years after transplantation.
In our experience, although short-term outcome was inferior
in the group transplanted with lungs after EVLP compared to
conventional lungs, the medium-term follow-up showed similar
results between groups. EVLP seems to be a safe method of
increasing the availability of transplantable organs.
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